No Cover Image

Journal article 634 views 127 downloads

Characterization and <i>ex vivo</i> evaluation of curcumin nanoethosomes for melanoma treatment

Rajesh Sreedharan Nair Orcid Logo, Nashiru Billa Orcid Logo, Lim Yang Mooi Orcid Logo, Andrew Morris Orcid Logo

Pharmaceutical Development and Technology, Volume: 27, Issue: 1, Pages: 72 - 82

Swansea University Author: Andrew Morris Orcid Logo

  • 59051.pdf

    PDF | Accepted Manuscript

    Released under the terms of a Creative Commons Attribution Non-Commercial License (CC-BY-NC)

    Download (636.57KB)

Check full text

DOI (Published version): 10.1080/10837450.2021.2023568

Abstract

This study aimed at developing curcumin nanoethosomes (Cur-Ets) with superior skin permeation intended for melanoma treatment. Although curcumin is active against many types of skin cancers, a suitable topical formulation is still lacking due to its hydrophobicity and poor skin permeation. The formu...

Full description

Published in: Pharmaceutical Development and Technology
ISSN: 1083-7450 1097-9867
Published: Informa UK Limited 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa59051
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2022-01-04T09:01:10Z
last_indexed 2022-03-17T04:27:54Z
id cronfa59051
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-03-16T12:08:57.8970798</datestamp><bib-version>v2</bib-version><id>59051</id><entry>2021-12-29</entry><title>Characterization and &lt;i&gt;ex vivo&lt;/i&gt; evaluation of curcumin nanoethosomes for melanoma treatment</title><swanseaauthors><author><sid>3d7a7f540a5143114fcaf67e4c68d151</sid><ORCID>0000-0002-6315-7553</ORCID><firstname>Andrew</firstname><surname>Morris</surname><name>Andrew Morris</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2021-12-29</date><deptcode>PHAR</deptcode><abstract>This study aimed at developing curcumin nanoethosomes (Cur-Ets) with superior skin permeation intended for melanoma treatment. Although curcumin is active against many types of skin cancers, a suitable topical formulation is still lacking due to its hydrophobicity and poor skin permeation. The formulation was characterized using Scanning Transmission Electron Microscopy (STEM), atomic force microscopy (AFM), ATR-FTIR, DSC, and XRD. In vitro skin permeation was carried out using human skin, and the cytotoxicity of the formulation was evaluated on human melanoma cells (SK-MEL28). The vesicle size and zeta potential of the Cur-Ets were determined as 67&#x2009;&#xB1;&#x2009;1.6&#x2009;nm and - 87.3&#x2009;&#xB1;&#x2009;3.3&#x2009;mV, respectively. STEM and AFM analysis further support the size and morphology of the formulation. Curcumin's compatibility with formulation additives was confirmed by ATR-FTIR analysis. In addition, DSC and XRD analyses showed successful drug encapsulation in nanoethosomes. The drug encapsulation efficiency was determined as 87&#x2009;&#xB1;&#x2009;0.9%. The skin permeation of curcumin from Cur-Ets showed a superior flux (0.14&#x2009;&#xB1;&#x2009;0.03 &#xB5;g cm&#x2212;2 h&#x2212;1) compared to the control (p&#x2009;&lt;&#x2009;0.05). Cytotoxicity of the formulation demonstrated a time-dependent and concentration-dependent antiproliferative activity against melanoma cells. The developed Cur-Ets is suggested as a promising topical formulation for melanoma treatment.</abstract><type>Journal Article</type><journal>Pharmaceutical Development and Technology</journal><volume>27</volume><journalNumber>1</journalNumber><paginationStart>72</paginationStart><paginationEnd>82</paginationEnd><publisher>Informa UK Limited</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1083-7450</issnPrint><issnElectronic>1097-9867</issnElectronic><keywords>curcumin; melanoma; nanoethosomes; human skin; permeation; cytotoxicity</keywords><publishedDay>6</publishedDay><publishedMonth>1</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-01-06</publishedDate><doi>10.1080/10837450.2021.2023568</doi><url/><notes/><college>COLLEGE NANME</college><department>Pharmacy</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>PHAR</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2022-03-16T12:08:57.8970798</lastEdited><Created>2021-12-29T20:34:12.2413385</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Rajesh Sreedharan</firstname><surname>Nair</surname><orcid>0000-0002-8540-5044</orcid><order>1</order></author><author><firstname>Nashiru</firstname><surname>Billa</surname><orcid>0000-0002-8496-1882</orcid><order>2</order></author><author><firstname>Lim Yang</firstname><surname>Mooi</surname><orcid>0000-0003-1377-7655</orcid><order>3</order></author><author><firstname>Andrew</firstname><surname>Morris</surname><orcid>0000-0002-6315-7553</orcid><order>4</order></author></authors><documents><document><filename>59051__22014__c8c088793388406395fde9418d3be148.pdf</filename><originalFilename>59051.pdf</originalFilename><uploaded>2022-01-04T16:46:47.0405772</uploaded><type>Output</type><contentLength>651850</contentLength><contentType>application/pdf</contentType><version>Accepted Manuscript</version><cronfaStatus>true</cronfaStatus><embargoDate>2022-12-27T00:00:00.0000000</embargoDate><documentNotes>Released under the terms of a Creative Commons Attribution Non-Commercial License (CC-BY-NC)</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-03-16T12:08:57.8970798 v2 59051 2021-12-29 Characterization and <i>ex vivo</i> evaluation of curcumin nanoethosomes for melanoma treatment 3d7a7f540a5143114fcaf67e4c68d151 0000-0002-6315-7553 Andrew Morris Andrew Morris true false 2021-12-29 PHAR This study aimed at developing curcumin nanoethosomes (Cur-Ets) with superior skin permeation intended for melanoma treatment. Although curcumin is active against many types of skin cancers, a suitable topical formulation is still lacking due to its hydrophobicity and poor skin permeation. The formulation was characterized using Scanning Transmission Electron Microscopy (STEM), atomic force microscopy (AFM), ATR-FTIR, DSC, and XRD. In vitro skin permeation was carried out using human skin, and the cytotoxicity of the formulation was evaluated on human melanoma cells (SK-MEL28). The vesicle size and zeta potential of the Cur-Ets were determined as 67 ± 1.6 nm and - 87.3 ± 3.3 mV, respectively. STEM and AFM analysis further support the size and morphology of the formulation. Curcumin's compatibility with formulation additives was confirmed by ATR-FTIR analysis. In addition, DSC and XRD analyses showed successful drug encapsulation in nanoethosomes. The drug encapsulation efficiency was determined as 87 ± 0.9%. The skin permeation of curcumin from Cur-Ets showed a superior flux (0.14 ± 0.03 µg cm−2 h−1) compared to the control (p < 0.05). Cytotoxicity of the formulation demonstrated a time-dependent and concentration-dependent antiproliferative activity against melanoma cells. The developed Cur-Ets is suggested as a promising topical formulation for melanoma treatment. Journal Article Pharmaceutical Development and Technology 27 1 72 82 Informa UK Limited 1083-7450 1097-9867 curcumin; melanoma; nanoethosomes; human skin; permeation; cytotoxicity 6 1 2022 2022-01-06 10.1080/10837450.2021.2023568 COLLEGE NANME Pharmacy COLLEGE CODE PHAR Swansea University 2022-03-16T12:08:57.8970798 2021-12-29T20:34:12.2413385 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Rajesh Sreedharan Nair 0000-0002-8540-5044 1 Nashiru Billa 0000-0002-8496-1882 2 Lim Yang Mooi 0000-0003-1377-7655 3 Andrew Morris 0000-0002-6315-7553 4 59051__22014__c8c088793388406395fde9418d3be148.pdf 59051.pdf 2022-01-04T16:46:47.0405772 Output 651850 application/pdf Accepted Manuscript true 2022-12-27T00:00:00.0000000 Released under the terms of a Creative Commons Attribution Non-Commercial License (CC-BY-NC) true eng https://creativecommons.org/licenses/by-nc/4.0/
title Characterization and <i>ex vivo</i> evaluation of curcumin nanoethosomes for melanoma treatment
spellingShingle Characterization and <i>ex vivo</i> evaluation of curcumin nanoethosomes for melanoma treatment
Andrew Morris
title_short Characterization and <i>ex vivo</i> evaluation of curcumin nanoethosomes for melanoma treatment
title_full Characterization and <i>ex vivo</i> evaluation of curcumin nanoethosomes for melanoma treatment
title_fullStr Characterization and <i>ex vivo</i> evaluation of curcumin nanoethosomes for melanoma treatment
title_full_unstemmed Characterization and <i>ex vivo</i> evaluation of curcumin nanoethosomes for melanoma treatment
title_sort Characterization and <i>ex vivo</i> evaluation of curcumin nanoethosomes for melanoma treatment
author_id_str_mv 3d7a7f540a5143114fcaf67e4c68d151
author_id_fullname_str_mv 3d7a7f540a5143114fcaf67e4c68d151_***_Andrew Morris
author Andrew Morris
author2 Rajesh Sreedharan Nair
Nashiru Billa
Lim Yang Mooi
Andrew Morris
format Journal article
container_title Pharmaceutical Development and Technology
container_volume 27
container_issue 1
container_start_page 72
publishDate 2022
institution Swansea University
issn 1083-7450
1097-9867
doi_str_mv 10.1080/10837450.2021.2023568
publisher Informa UK Limited
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description This study aimed at developing curcumin nanoethosomes (Cur-Ets) with superior skin permeation intended for melanoma treatment. Although curcumin is active against many types of skin cancers, a suitable topical formulation is still lacking due to its hydrophobicity and poor skin permeation. The formulation was characterized using Scanning Transmission Electron Microscopy (STEM), atomic force microscopy (AFM), ATR-FTIR, DSC, and XRD. In vitro skin permeation was carried out using human skin, and the cytotoxicity of the formulation was evaluated on human melanoma cells (SK-MEL28). The vesicle size and zeta potential of the Cur-Ets were determined as 67 ± 1.6 nm and - 87.3 ± 3.3 mV, respectively. STEM and AFM analysis further support the size and morphology of the formulation. Curcumin's compatibility with formulation additives was confirmed by ATR-FTIR analysis. In addition, DSC and XRD analyses showed successful drug encapsulation in nanoethosomes. The drug encapsulation efficiency was determined as 87 ± 0.9%. The skin permeation of curcumin from Cur-Ets showed a superior flux (0.14 ± 0.03 µg cm−2 h−1) compared to the control (p < 0.05). Cytotoxicity of the formulation demonstrated a time-dependent and concentration-dependent antiproliferative activity against melanoma cells. The developed Cur-Ets is suggested as a promising topical formulation for melanoma treatment.
published_date 2022-01-06T04:16:03Z
_version_ 1763754076828336128
score 11.028798

Similar Items